Administration of Fingolimod in Greek Patients With Multiple Sclerosis.

Inclusion Criteria

• •1. Patients over 18 years of age.
• •2. Consent and compliance of participants with the treatments and procedures of the study.
• •3. Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) according to the revised McDonald 2017 criteria.
• •4. Patients who are receiving fingolimod, according to the drug's Summary of product Characteristics (SmPC).
• •5. Patients with available follow-up data for at least 12 months prior to their inclusion in the study, which are sufficient to calculate the annualized relapse rate.